New Oral Antithrombotics: Focus on Dabigatran, an Oral, Reversible Direct Thrombin Inhibitor for the Prevention and Treatment of Venous and Arterial Thromboembolic Disorders

Vascular Health and Risk Management
doi 10.2147/vhrm.s26482
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Effects of the Oral, Direct Thrombin Inhibitor Dabigatran on Five Common Coagulation Assays

Thrombosis and Haemostasis
Hematology
2011English

Oral Anticoagulants in the Treatment of Venous Thromboembolic Complications: Focus on Apixaban

Medical Council
2017English

Therapeutic Promise of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor in a Preclinical Model of Colon Carcinogenesis

Clinical and Experimental Pharmacology
2018English

Prevention and Treatment of Venous Thromboembolic Disease

Prescriber
Pharmacology
2018English

Prevention and Treatment of Venous Thromboembolism With New Oral Anticoagulants: A Practical Update for Clinicians

Thrombosis
Cardiovascular MedicineHematologyCardiology
2013English

A Cost-Effectiveness Analysis of Novel Oral Anticoagulants for Primary Prevention of Venous Thromboembolic Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Effect of the Oral Thrombin Inhibitor Dabigatran on Allergic Lung Inflammation Induced by Repeated House Dust Mite Administration in Mice

American Journal of Physiology - Lung Cellular and Molecular Physiology
PulmonaryRespiratory MedicinePhysiologyCell Biology
2015English

The Treatment of Venous Thromboembolism With New Oral Anticoagulants

Italian Journal of Medicine
Medicine
2013English

New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities

Drugs
Pharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy